Man Group
BCRX icon

Man Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Man Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.3M Buy
1,293,300
+885,450
+217% +$6.88M 0.03% 717
2025
Q4 		$3.18M Buy
407,850
+53,366
+15% +$386K 0.01% 1265
2025
Q3 		$2.69M Sell
354,484
-67,286
-16% -$560K 0.01% 1301
2025
Q2 		$3.78M Buy
421,770
+189,407
+82% +$1.76M 0.01% 1174
2025
Q1 		$1.74M Buy
232,363
+142,409
+158% +$1.15M 0.01% 1410
2024
Q4 		$676K Buy
89,954
+28,481
+46% +$216K ﹤0.01% 1588
2024
Q3 		$467K Buy
+61,473
New +$467K ﹤0.01% 1673
2023
Q2 		– Hold
0
– -$3.46M – 1977
2023
Q1 		– Hold
0
– – – 969
2020
Q1 		– Sell
-24,300
Closed -$84K – 1618
2019
Q4 		$84K Buy
+24,300
New +$61.1K ﹤0.01% 1802

Other funds holding BCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return